Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19 : A Multicenter Study
The primary objective of this multicenter, observational, retrospective study was to assess the incidence rate of ventilator-associated pneumonia (VAP) in coronavirus disease 2019 (COVID-19) patients in intensive care units (ICU). The secondary objective was to assess predictors of 30-day case-fatality of VAP. From 15 February to 15 May 2020, 586 COVID-19 patients were admitted to the participating ICU. Of them, 171 developed VAP (29%) and were included in the study. The incidence rate of VAP was of 18 events per 1000 ventilator days (95% confidence intervals [CI] 16-21). Deep respiratory cultures were available and positive in 77/171 patients (45%). The most frequent organisms were Pseudomonas aeruginosa (27/77, 35%) and Staphylococcus aureus (18/77, 23%). The 30-day case-fatality of VAP was 46% (78/171). In multivariable analysis, septic shock at VAP onset (odds ratio [OR] 3.30, 95% CI 1.43-7.61, p = 0.005) and acute respiratory distress syndrome at VAP onset (OR 13.21, 95% CI 3.05-57.26, p < 0.001) were associated with fatality. In conclusion, VAP is frequent in critically ill COVID-19 patients. The related high fatality is likely the sum of the unfavorable prognostic impacts of the underlying viral and the superimposed bacterial diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 10(2021), 4 vom: 03. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.03.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm10040555 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321066650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321066650 | ||
| 003 | DE-627 | ||
| 005 | 20231225175025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm10040555 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321066650 | ||
| 035 | |a (NLM)33546093 | ||
| 035 | |a (PII)555 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giacobbe, Daniele Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19 |b A Multicenter Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.03.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The primary objective of this multicenter, observational, retrospective study was to assess the incidence rate of ventilator-associated pneumonia (VAP) in coronavirus disease 2019 (COVID-19) patients in intensive care units (ICU). The secondary objective was to assess predictors of 30-day case-fatality of VAP. From 15 February to 15 May 2020, 586 COVID-19 patients were admitted to the participating ICU. Of them, 171 developed VAP (29%) and were included in the study. The incidence rate of VAP was of 18 events per 1000 ventilator days (95% confidence intervals [CI] 16-21). Deep respiratory cultures were available and positive in 77/171 patients (45%). The most frequent organisms were Pseudomonas aeruginosa (27/77, 35%) and Staphylococcus aureus (18/77, 23%). The 30-day case-fatality of VAP was 46% (78/171). In multivariable analysis, septic shock at VAP onset (odds ratio [OR] 3.30, 95% CI 1.43-7.61, p = 0.005) and acute respiratory distress syndrome at VAP onset (OR 13.21, 95% CI 3.05-57.26, p < 0.001) were associated with fatality. In conclusion, VAP is frequent in critically ill COVID-19 patients. The related high fatality is likely the sum of the unfavorable prognostic impacts of the underlying viral and the superimposed bacterial diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a VAP | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a ventilation | |
| 700 | 1 | |a Battaglini, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Enrile, Elisa Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Dentone, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Vena, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Robba, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Ball, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoletti, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Coloretti, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Di Bella, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Di Biagio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetti, Iole |e verfasserin |4 aut | |
| 700 | 1 | |a Mikulska, Malgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Carannante, Novella |e verfasserin |4 aut | |
| 700 | 1 | |a De Maria, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Magnasco, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Maraolo, Alberto Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Mirabella, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Montrucchio, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Patroniti, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Taramasso, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Tiseo, Giusy |e verfasserin |4 aut | |
| 700 | 1 | |a Fornaro, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Fraganza, Fiorentino |e verfasserin |4 aut | |
| 700 | 1 | |a Monastra, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Roman-Pognuz, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Paluzzano, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorentino, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Corcione, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bussini, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Pascale, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Corcione, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Tonetti, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Falcone, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Biagioni, Emanuela |e verfasserin |4 aut | |
| 700 | 1 | |a Ranieri, Vito Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Giannella, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a De Rosa, Francesco Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Girardis, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Menichetti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Pelosi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 10(2021), 4 vom: 03. Feb. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:4 |g day:03 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm10040555 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 4 |b 03 |c 02 | ||